KLRK1 and prostate carcinoma: NKG2D itself is an important mediator of tumor immuno-surveillance, since animals deficient for NKG2D demonstrate a reduced ability to fight prostate carcinoma and B cell lymphoma, but not chemically induced fibrosarcoma (35).